Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Enanta Pharmaceutica (ENTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,668,123
  • Shares Outstanding, K 19,442
  • Annual Sales, $ 206,630 K
  • Annual Income, $ 71,960 K
  • 60-Month Beta 1.38
  • Price/Sales 8.01
  • Price/Cash Flow 22.40
  • Price/Book 3.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.07
  • Number of Estimates 4
  • High Estimate 0.20
  • Low Estimate -0.30
  • Prior Year 0.61
  • Growth Rate Est. (year over year) -111.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.54 +2.71%
on 04/18/19
104.69 -18.04%
on 03/19/19
-16.77 (-16.35%)
since 03/18/19
3-Month
73.93 +16.06%
on 01/24/19
106.80 -19.66%
on 03/04/19
+8.90 (+11.57%)
since 01/18/19
52-Week
64.08 +33.88%
on 12/24/18
127.77 -32.85%
on 07/06/18
-1.63 (-1.86%)
since 04/18/18

Most Recent Stories

More News
Enanta Pharmaceu Falls 2.58% on Heavy Volume: Watch For Potential Rebound

Enanta Pharmaceu (NASDAQ:ENTA) traded in a range yesterday that spanned from a low of $89.76 to a high of $92.17. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of...

ENTA : 85.80 (+0.78%)
Enanta Pharmaceuticals Presents New Preclinical Data on Compounds Targeting Hepatitis B Virus and Non-Alcoholic Steatohepatitis at The International Liver Congress(TM) 2019

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced...

ENTA : 85.80 (+0.78%)
AbbVie's MAVIRET(TM) now reimbursed in Quebec

AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company announced today that MAVIRET(TM) (glecaprevir/pibrentasvir tablets) is now listed as a medication covered under Quebec's...

ENTA : 85.80 (+0.78%)
ABBV : 77.57 (-0.53%)
Market Trends Toward New Normal in Tesla, Zuora, SunOpta, Internap, Enanta Pharmaceuticals, and Hilton Grand Vacations -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tesla, Inc. (NASDAQ:TSLA),...

TSLA : 273.26 (+0.75%)
STKL : 3.30 (+1.54%)
ZUO : 19.22 (-1.69%)
INAP : 4.38 (-5.19%)
ENTA : 85.80 (+0.78%)
HGV : 32.67 (-0.31%)
Enanta Pharmaceu Shares Down 2.8% Since SmarTrend's Sell Call (ENTA)

SmarTrend identified a Downtrend for Enanta Pharmaceu (NASDAQ:ENTA) on March 25th, 2019 at $95.15. In approximately 2 weeks, Enanta Pharmaceu has returned 2.84% as of today's recent price of $92.45.

ENTA : 85.80 (+0.78%)
AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET(TM)

AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company, announced that MAVIRETTM (glecaprevir/pibrentasvir tablets) is now reimbursed in Alberta, Saskatchewan and the Non-Insured...

ENTA : 85.80 (+0.78%)
ABBV : 77.57 (-0.53%)
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

CELG : 93.76 (-0.57%)
ENTA : 85.80 (+0.78%)
PBYI : 32.89 (+0.09%)
EXEL : 20.90 (-2.15%)
SAGE : 164.73 (+2.02%)
Biotech Stocks Outperform During Inversions: 5 Must Watch

An inverted yield curve signals a recession but it is often bullish for biotech stocks.

CELG : 93.76 (-0.57%)
ENTA : 85.80 (+0.78%)
PBYI : 32.89 (+0.09%)
EXEL : 20.90 (-2.15%)
SAGE : 164.73 (+2.02%)
PFE : 39.38 (-1.25%)
BMY : 45.52 (-0.61%)
Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress(TM) 2019

--FXR agonist EDP-305 targeting NASH

ENTA : 85.80 (+0.78%)
British Columbia PharmaCare Lists AbbVie's Hepatitis C Treatment MAVIRET(TM) on its Formulary

AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company, announced that MAVIRETTM (glecaprevir/pibrentasvir tablets) is now reimbursed in British Columbia. MAVIRET is a...

ENTA : 85.80 (+0.78%)
ABBV : 77.57 (-0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ENTA with:

Business Summary

Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown,...

See More

Key Turning Points

2nd Resistance Point 89.09
1st Resistance Point 87.44
Last Price 85.80
1st Support Level 83.85
2nd Support Level 81.90

See More

52-Week High 127.77
Fibonacci 61.8% 103.44
Fibonacci 50% 95.93
Fibonacci 38.2% 88.41
Last Price 85.80
52-Week Low 64.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar